Anti-Scl-70
EstablishedAnti-Scl-70 is a specific marker for diffuse systemic sclerosis, associated with higher interstitial lung disease risk.
This antibody is a specific marker for a more severe, widespread form of scleroderma, a disease that hardens skin and connective tissue. Testing positive raises particular concern for lung involvement, so doctors watch lung function especially closely in these patients.
Anti-Scl-70 (anti-topoisomerase I) antibodies target a nuclear enzyme and are a specific serologic marker for diffuse cutaneous systemic sclerosis (scleroderma), completing the classic scleroderma/myositis antibody panel alongside the SS-A/Ro and SS-B/La antibodies already covered in this biomarker set.
Positive anti-Scl-70 supports a diffuse systemic sclerosis diagnosis and is associated with higher risk of interstitial lung disease and more extensive skin involvement compared to the anti-centromere antibody pattern, which instead points toward limited disease.
Measured via immunoassay (ELISA) as part of an extractable nuclear antigen (ENA) panel, typically ordered alongside anti-centromere antibody and ANA testing when scleroderma is clinically suspected based on skin changes, Raynaud's phenomenon, or unexplained interstitial lung disease.
Anti-Scl-70 positivity supports closer pulmonary surveillance (baseline and serial pulmonary function testing, high-resolution CT) given the associated interstitial lung disease risk, which is a leading cause of mortality in systemic sclerosis and a key driver of treatment intensity decisions.
Positivity prompts closer pulmonary surveillance given the strong association with lung involvement and mortality risk.
- General rheumatology reference literature on anti-Scl-70/anti-topoisomerase I antibody in diffuse systemic sclerosis.